Trials / Completed
CompletedNCT04376593
PET/CT Imaging in COVID-19 Patients
18F-αvβ6-binding-peptide PET/CT in Patients Post SARS CoV2 Infection
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- University of California, Davis · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a PET/CT study using the 18F-αvβ6-binding-peptide.The goal of this study is to evaluate this peptide in patients after infection with SARS CoV2.
Detailed description
The goal of the study is to to acquire 18F-αvβ6-BP PET/CT images in patients diagnosed with SARS CoV2 and to demonstrate the ability of 18F-αvβ6-BP to detect lung damage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-αvβ6-BP | Subjects will be injected once per imaging session (a maximum of 3 imaging sessions) with up to 10 mCi (±20%) of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 secs). |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2026-02-23
- Completion
- 2026-02-23
- First posted
- 2020-05-06
- Last updated
- 2026-03-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04376593. Inclusion in this directory is not an endorsement.